Article Text

other Versions

Interferon-free treatment for genotypes 2 and 3 patients with hepatitis C
  1. Nowlan Selvapatt1,
  2. Philip Hendy2
  1. 1Department of Hepatology, Imperial College Healthcare, London, UK
  2. 2IBD Unit, St Mark's Hospital, London, UK
  1. Correspondence to Dr Philip Hendy, IBD Unit, St Mark's Hospitaql, Watford Rd, Harrow, London HA1 3UJ, UK; philiphendy14{at}

Statistics from

Sofosbuvir and ribavirin in HCV genotypes 2 and 3

▸ Zeuzem S, Dusheiko G, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370:21.

▸ Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in Patients without Treatment Options. N Engl J Med 2013;368:1867–77.

This paper reviews the outcomes of the VALENCE study which evaluated an interferon-free treatment regime for patients with genotypes 2 and 3 hepatitis C virus (HCV).1 While demonstrating promising efficacy in the treatment of genotype 2 infected patients and certain subtypes of patients with genotype 3 infection, it also provides a timely reminder that careful patient selection is required.

Sofosbuvir (trade name Sovaldi) is an oral direct acting antiviral agent (NS5B polymerase inhibitor) licensed in the UK for the treatment of hepatitis C. It is currently under review at the National Institute for Health and Care Excellence. The study was designed as a phase III blinded placebo controlled trial of treatment of genotype 2 and 3 …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.